170 related articles for article (PubMed ID: 32272902)
1. Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression.
Meng C; Zou Y; Hong W; Bao C; Jia X
Mol Med; 2020 Apr; 26(1):33. PubMed ID: 32272902
[TBL] [Abstract][Full Text] [Related]
2. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients.
Wu CC; Ekanem TI; Phan NN; Loan DTT; Hou SY; Lee KH; Wang CY
Int J Med Sci; 2020; 17(18):3112-3124. PubMed ID: 33173433
[TBL] [Abstract][Full Text] [Related]
4. PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth.
Xiang W; Wu X; Huang C; Wang M; Zhao X; Luo G; Li Y; Jiang G; Xiao X; Zeng F
Oncotarget; 2017 Jan; 8(1):664-678. PubMed ID: 27893422
[TBL] [Abstract][Full Text] [Related]
5. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population.
Yoon CH; Kim MJ; Lee H; Kim RK; Lim EJ; Yoo KC; Lee GH; Cui YH; Oh YS; Gye MC; Lee YY; Park IC; An S; Hwang SG; Park MJ; Suh Y; Lee SJ
J Biol Chem; 2012 Jun; 287(23):19516-27. PubMed ID: 22511756
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
[TBL] [Abstract][Full Text] [Related]
7. Pttg1 Promotes Growth of Breast Cancer through P27 Nuclear Exclusion.
Xiea Y; Wangb R
Cell Physiol Biochem; 2016; 38(1):393-400. PubMed ID: 26824458
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer.
Jiang R; Sun Y; Chen X; Shi P
Breast Cancer Res Treat; 2021 Nov; 190(2):203-211. PubMed ID: 34519905
[TBL] [Abstract][Full Text] [Related]
9. Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein.
Chen PY; Tien HJ; Chen SF; Horng CT; Tang HL; Jung HL; Wu MJ; Yen JH
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29649138
[TBL] [Abstract][Full Text] [Related]
10. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
11. RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells.
Huang SQ; Liao QJ; Wang XW; Xin DQ; Chen SX; Wu QJ; Ye G
Braz J Med Biol Res; 2012 Nov; 45(11):995-1001. PubMed ID: 22872288
[TBL] [Abstract][Full Text] [Related]
12.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
13. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
14. The ERĪ±-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
15. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.
Lee YM; Lee JY; Ho CC; Hong QS; Yu SL; Tzeng CR; Yang PC; Chen HW
Breast Cancer Res; 2011; 13(6):R116. PubMed ID: 22113133
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
Li JD; Farah AA; Huang ZG; Zhai GQ; Wang RG; Liu JL; Wang QJ; Zhang GL; Lei ZL; Dang YW; Li SH
BMC Cancer; 2022 Jun; 22(1):713. PubMed ID: 35768832
[TBL] [Abstract][Full Text] [Related]
18. The clinical value and biological function of PTTG1 in colorectal cancer.
Ren Q; Jin B
Biomed Pharmacother; 2017 May; 89():108-115. PubMed ID: 28219049
[TBL] [Abstract][Full Text] [Related]
19. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
[TBL] [Abstract][Full Text] [Related]
20. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.
Huang L; Zhao S; Frasor JM; Dai Y
PLoS One; 2011; 6(7):e22274. PubMed ID: 21789246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
